MCK Quantitative Stock Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2025
0mins
Source: NASDAQ.COM
MCKESSON CORP Analysis: MCKESSON CORP (MCK) received a high rating of 93% from Validea's Multi-Factor Investor model, indicating strong interest based on its low volatility, momentum, and high net payout yields in the Major Drugs industry.
Pim van Vliet's Strategy: The investment strategy developed by Pim van Vliet emphasizes that low volatility stocks can outperform high volatility ones with less risk, supported by his research and publication on conservative factor investing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCK
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 942.83 USD with a low forecast of 880.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 834.180
Low
880.00
Averages
942.83
High
1000.00
Current: 834.180
Low
880.00
Averages
942.83
High
1000.00
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
McKesson Declares Quarterly Dividend of $0.82 per Share
- Quarterly Dividend Announcement: McKesson declares a quarterly dividend of $0.82 per share, consistent with previous distributions, indicating stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 0.39% reflects the company's robust performance in the current market environment, potentially attracting income-seeking investors looking for stability.
- Shareholder Record Date: The dividend will be payable on April 1, with a record date of March 2 and an ex-dividend date also on March 2, ensuring shareholders receive their payouts promptly, thereby strengthening the shareholder base.
- 2026 Earnings Guidance: McKesson raises its 2026 EPS guidance to $38.35–$38.85, indicating ongoing advancements in oncology and specialty platforms, which enhances market confidence in the company's future growth prospects.
Continue Reading
JPMorgan Conference Highlights GLP-1 Drug Market Potential
- GLP-1 Drug Outlook: Insights from the 44th JPMorgan Healthcare Conference indicate that GLP-1 drugs are poised to become the largest drug class in history, potentially generating billions in revenue for pharmaceutical companies.
- High Conference Attendance: The conference saw unprecedented participation from pharmaceutical companies, with crowded venues reflecting strong investor interest and demand for new drug developments, significantly higher than in the past decade.
- Regulatory Impact: The Biden administration's FTC has tightened regulations on Big Pharma's acquisitions of smaller firms, leading to decreased investment activity in the sector and negatively affecting stock performance for companies like Danaher.
- Competitive Landscape: Eli Lilly's leading position in the GLP-1 market is expected to capture significant market share, with its oral formulation anticipated to receive approval this spring, further solidifying its competitive advantage.
Continue Reading